Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Cash Flow (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Net Cash Flow data on record, last reported at $302.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 14.41% year-over-year to $302.2 million; the TTM value through Dec 2025 reached $180.3 million, down 6.27%, while the annual FY2025 figure was $180.3 million, 6.27% down from the prior year.
  • Net Cash Flow reached $302.2 million in Q4 2025 per PTCT's latest filing, up from -$340.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $695.2 million in Q1 2025 and bottomed at -$476.4 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $38.7 million, with a median of -$7.8 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 4371.86% in 2022, then plummeted 536.62% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $3.8 million in 2021, then soared by 4371.86% to $169.4 million in 2022, then soared by 151.35% to $425.8 million in 2023, then plummeted by 37.95% to $264.2 million in 2024, then rose by 14.41% to $302.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $302.2 million in Q4 2025, -$340.7 million in Q3 2025, and -$476.4 million in Q2 2025.